Reviewing Insmed (NASDAQ:INSM) and Nurix Therapeutics (NASDAQ:NRIX)

Insmed (NASDAQ:INSM) and Nurix Therapeutics (NASDAQ:NRIX) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.

Earnings and Valuation

This table compares Insmed and Nurix Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insmed	$606.42 million	44.91	-$1.28 billion	($4.11)	-30.35
Nurix Therapeutics	$83.98 million	32.36	-$264.46 million	($3.45)	-7.59

Nurix Therapeutics has lower revenue, but higher earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Nurix Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Insmed and Nurix Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Insmed	-76.94%	-123.94%	-44.30%
Nurix Therapeutics	-928.44%	-76.09%	-57.31%

Analyst Ratings

This is a summary of recent recommendations for Insmed and Nurix Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insmed	1	0	22	2	3.00
Nurix Therapeutics	1	1	13	0	2.80

Insmed presently has a consensus target price of $205.52, suggesting a potential upside of 64.79%. Nurix Therapeutics has a consensus target price of $34.21, suggesting a potential upside of 30.66%. Given Insmed’s stronger consensus rating and higher probable upside, equities research analysts clearly believe Insmed is more favorable than Nurix Therapeutics.

Volatility and Risk

Insmed has a beta of 0.82, suggesting that its share price is 18% less volatile than the S&P 500. Comparatively, Nurix Therapeutics has a beta of 1.8, suggesting that its share price is 80% more volatile than the S&P 500.

Summary

Insmed beats Nurix Therapeutics on 8 of the 13 factors compared between the two stocks.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed’s earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

About Nurix Therapeutics

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.